Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
3 May 2017
Question for written answer
to the Commission
Rule 130
Lola Sánchez Caldentey (GUE/NGL)

 Subject:  Access to affordable and effective cancer treatments

Access to affordable and effective cancer treatments is a growing concern both within the EU and worldwide.

At the World Health Organisation on Monday 13 March 2017, the intersessional drafting group, counting EU representatives among its members, held a meeting to discuss the Cancer Resolution to be considered at the World Health Assembly in Geneva in May 2017.

A number of WHO Member States have proposed the addition of a new paragraph to the Resolution, with the following wording: ‘to prepare a technical report towards the end of 2018 on existing mechanisms and options for R&D for cancer medicines, including the delinkage between R&D costs and product prices, that would enhance affordability and accessibility of these products’.

1. According to reliable sources, the EU opposes this proposal. Is this true, and if so, what are its underlying motivations?

2. Could the Commission brief me on the EU’s position (represented by the Commission and the EEAS) on the above text and the institutional procedure through which it was adopted?

Last updated: 16 May 2017Legal notice